诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

已收盘 07-07 16:00:00 EDT

49.64

+0.38

+0.77%

盘后49.63

-0.01-0.02%

19:59 EDT

最高50.44	最低49.31	成交量1,222万
今开50.29	昨收49.26	日振幅2.30%
总市值2,204亿	流通市值1,582亿	总股本44.39亿
成交额6.08亿	换手率0.38%	流通股本31.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":49.64,"timestamp":1783454400000,"preClose":49.26,"halted":0,"volume":12222735,"hourTrading":{"tag":"盘后","latestPrice":49.6307,"preClose":49.64,"latestTime":"19:59 EDT","volume":2307881,"amount":114559808.6274,"timestamp":1783468782990,"change":-0.0093,"changeRate":-0.000187,"amplitude":0.004029},"delay":0,"changeRate":0.00771416971173371,"floatShares":3187922885,"shares":4439052849,"eps":4.228648,"marketStatus":"已收盘","change":0.38,"latestTime":"07-07 16:00:00 EDT","open":50.2928,"high":50.44,"low":49.305,"amount":608122256.8669499,"amplitude":0.023041,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.228648,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783497600000},"marketStatusCode":5,"adr":1,"adrRate":1,"listingDate":363499200000,"exchange":"NYSE","adjPreClose":49.26,"dividendRate":0.034688,"preHourTrading":{"tag":"盘前","latestPrice":50.34,"preClose":49.26,"latestTime":"09:29 EDT","volume":159489,"amount":8002463.923872001,"timestamp":1783430999665,"change":1.08,"changeRate":0.021924,"amplitude":0.013804},"postHourTrading":{"tag":"盘后","latestPrice":49.6307,"preClose":49.64,"latestTime":"19:59 EDT","volume":2307881,"amount":114559808.6274,"timestamp":1783468782990,"change":-0.0093,"changeRate":-0.000187,"amplitude":0.004029},"volumeRatio":1.140919,"impliedVol":0.4638,"impliedVolPercentile":0.3426},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"1159320796","title":"异动解读｜诺和诺德盘中下跌3.05%，报48.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159320796","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159320796?lang=zh_cn&edition=full","pubTime":"2026-07-06 21:49","pubTimestamp":1783345799,"startTime":"0","endTime":"0","summary":"7月6日，诺和诺德盘中下跌3.05%，报48.70美元/股，成交额8019.73万美元。诺和诺德所在的制药行业中，整体表现疲弱，个股中，礼来跌2.0%，强生跌2.45%，辉瑞跌2.24%，默沙东跌1.94%，阿斯利康跌4.11%。Novo Nordisk A/S是一家全球性医疗保健公司，也是肥胖和糖尿病护理领域的世界领先企业，总部位于丹麦，业务遍及约80个国家，产品销往约170个国家。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649643191","title":"汇丰将诺和诺德目标价从280丹麦克朗上调至300丹麦克朗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2649643191","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649643191?lang=zh_cn&edition=full","pubTime":"2026-07-06 13:19","pubTimestamp":1783315176,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ1G4Q59.USD","LU2236285917.USD","LU0211326755.USD","LU0496365809.HKD","LU1267930227.SGD","NVOX","LU1093756168.USD","HSBC","BK4207","BK4532","LU0976567544.SGD","BK4521","00005","BK4588","PPH","IE00BKVL7J92.USD","NVOH","BK4599","LU0128525689.USD","LU0211326839.USD","LU0310800965.SGD","NVO","LU0052756011.USD","THNR","BK4585","HSBH","LU0154236417.USD","LU1093756325.SGD","OZEM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648685208","title":"诺和诺德(NVO)涨3.8% 施压供应商争取折扣 削减成本反攻减肥药市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2648685208","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648685208?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:24","pubTimestamp":1783002296,"startTime":"0","endTime":"0","summary":"消息面上，丹麦药企诺和诺德发函合作供应商，协商压低采购成本，意图扭转减肥药市场竞争劣势，抢夺礼来  占据的行业龙头地位。诺和诺德表示供应商参与让利并非强制要求，但让利成效将纳入后续合作评估维度。降本举措并非单一动作，今年 9 月诺和诺德推出大规模裁员计划，拟全球裁减 9000 名员工，叠加本次供应链压价，共同组成新任 CEO 主导的全面降本方案，依托压缩开支优化产品定价，争夺减肥药赛道市场份额。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/NTE3MzYyMzA2NDI2MjU=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NTE3MzYyMzA2NDI2MjU=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302165","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELIL","LU2168564222.USD","LU1366192091.USD","LU1989771016.USD","SG9999001176.USD","GB00BDT5M118.USD","LU2168563687.JPY","LU0266013472.USD","IE0009355771.USD","LU0203202063.USD","NVOX","LU1917777945.USD","LU2106854487.HKD","LU0353189680.USD","LU0114720955.EUR","LU0316494557.USD","LU2471134796.USD","IE0005OL40V9.USD","LU0823434740.USD","LU0466842654.USD","LU0154236417.USD","LU0109394709.USD","LU1720051108.HKD","LU2168564065.EUR","ELIS","LU1720051017.SGD","LU0158827948.USD","IE00BKVL7J92.USD","IE00BFSS8Q28.SGD","SG9999018865.SGD","LU2265009873.SGD","LU2089283258.USD","LU2471134523.USD","IE00B775H168.HKD","IE00B4R5TH58.HKD","LU1868836757.USD","LU2023251221.USD","LU0158827781.USD","LU2746668461.USD","LU1868836914.USD","LU2462157665.USD","IE00B1BXHZ80.USD","LU1127390331.HKD","LU1057294990.SGD","LU1551013425.SGD","LU2461242641.AUD","IE0001KFT4U8.USD","IE0004445239.USD","LU0238689110.USD","LU2750360997.AUD","SG9999014898.SGD","LLY","LU0354030511.USD","LU0456855351.SGD","LU0354030438.USD","LU1548497426.USD","SG9999015986.USD","LU0889565916.HKD","IE00B4JS1V06.HKD","LU0097036916.USD","LU0234572021.USD","SG9999014914.USD","IE0004445015.USD","LU2023250504.SGD","BK4599","LU2491050071.SGD","LU2168564149.EUR","SGXZ99366536.SGD","SG9999018857.SGD","LU2456880835.USD","SGXZ57979304.SGD","LU0006306889.USD","LU2111349929.HKD","LU1061106388.HKD","LU2552382058.USD","LU2552382132.HKD","LU0256863902.USD","LU0823416689.USD","LU1323610961.USD","LU1974910355.USD","LU2168564495.EUR","IE00B1XK9C88.USD","LU0640476718.USD","BK4581","LU0079474960.USD","LU2491049909.HKD","LU0094547139.USD","LU2112291526.USD","LU1983299246.USD","SGXZ51526630.SGD","LU2361045086.USD","LU1064131342.USD","LU0320765992.SGD","LU0106261372.USD","LU2417539215.USD","LU2756315664.SGD","IE00B2B36J28.USD","LU0256863811.USD","LU0133085943.USD","LU0708995401.HKD","LU1069344957.HKD","IE00BJJMRY28.SGD","LU0787776722.HKD","LU2237443465.HKD","LU0689472784.USD","BK4532","IE00BJT1NW94.SGD","LLYZ","LU1093756168.USD","LU1629891620.HKD","SG9999015945.SGD","LLII","LU0198837287.USD","LU0432979614.USD","LU1023059063.AUD","IE00BK4W5L77.USD","LU2491050154.USD","LU0345770993.USD","LU0061475181.USD","LU0882574139.USD","SG9999014906.USD","LU0203201768.USD","LU1280957306.USD","IE00BWXC8680.SGD","LU1551013342.USD","LU0289739699.SGD","LU1623119135.USD","LU0323591593.USD","LU2023250330.USD","LU2237443978.SGD","LU2357305700.SGD","LU2237443895.HKD","LU0672654240.SGD","LU0385154629.USD","LU1814569148.SGD","SGXZ81514606.USD","BK4533","LU0096364046.USD","BK4534","LU1868837136.USD","LU0820561818.USD","LU0417517546.SGD","LU0471298777.SGD","LU0058720904.USD","LU0882574055.USD","LU0964807845.USD","LU2089284900.SGD","BK4516","LU0320765059.SGD","IE00BKDWB100.SGD","LU0353189763.USD","LU2028103732.USD","LU2087625088.SGD","LU2089984988.USD","LU2211815571.USD","LU2471134879.HKD","LU2602419157.SGD","BK4588","LLYX","LU1712237335.SGD","LU2237443622.USD","LU0122379950.USD","BK4007","LU2361044865.SGD","IE00BN29S564.USD","SG9999017495.SGD","LU2237443382.USD","IE00BFTCPJ56.SGD","IE00BJJMRX11.SGD","LU1145028129.USD","LU1868837300.USD","SG9999013999.USD","IE00BK4W5M84.HKD","LU2237438978.USD","SG9999015978.USD","LU0345770308.USD","LU1232071149.USD","LU0823434583.USD","SGXZ31699556.SGD","NVO","IE00BKPKM429.USD","LU1093756325.SGD","LU2264538146.SGD","LU1804176565.USD","NVOH","LU2063271972.USD","LU0786609619.USD","LU0943347566.SGD","LU2756315318.SGD","LU2468319806.SGD","LU2552382215.SGD","LU0683600562.USD","LU1868836591.USD","LU2360106947.USD","LU2746668974.SGD","SG9999001176.SGD","LU2213496289.HKD","LU2324357040.USD","LU2361044949.HKD","LU2471134952.CNY","LU1035775433.USD","SG9999014880.SGD","LU1291159041.SGD","IE00B7KXQ091.USD","IE00BJLML261.HKD","LU0820561909.HKD","LU2271345857.HKD","LU0109391861.USD","IE00BJJMRZ35.SGD","LU0210536198.USD","LU0471298694.HKD","LU1267930730.SGD","LU0225283273.USD","LU2108987350.USD","LU2750360641.GBP","LU1988902786.USD","IE00BFSS7M15.SGD","LU2236285917.USD","IE0002141913.USD","LU2896262040.SGD","LU2237443549.SGD","SG9999015952.SGD","LU0820562030.AUD","BK4585","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176916059","title":"异动解读｜诺和诺德盘中上涨3.09%，Medicare覆盖落地叠加供应链降本举措提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1176916059","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176916059?lang=zh_cn&edition=full","pubTime":"2026-07-02 21:55","pubTimestamp":1783000532,"startTime":"0","endTime":"0","summary":"7月2日，诺和诺德盘中上涨3.09%，报50.355美元/股，成交额1.11亿美元。消息面上，美国联邦医疗保险自7月1日起首次将GLP-1类减肥药纳入常规报销体系，符合条件的Medicare参保患者可按月自付50美元购得Wegovy，政策利好持续发酵。同日，有报道称诺和诺德正寻求供应商降低原材料价格以维持市场竞争力，显示公司在需求放量的同时积极优化成本结构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176561117","title":"异动解读｜诺和诺德盘中上涨3.18%，美国联邦医保首次覆盖减肥药利好兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=1176561117","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176561117?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:34","pubTimestamp":1782916499,"startTime":"0","endTime":"0","summary":"7月1日，诺和诺德盘中上涨3.18%，报49.32美元/股，成交额1.6亿美元。消息面上，美国联邦医疗保险自7月1日起首次将GLP-1类减肥药物纳入常规报销体系，诺和诺德同日宣布符合条件的Medicare参保患者现可按月自付50美元购得Wegovy。值得注意的是，诺和诺德逆势走强，同行业礼来跌1.33%、阿斯利康跌2.93%、默沙东跌1.84%，板块整体承压下公司凭借政策直接利好独立走高。此前杰富瑞及高盛亦相继上调诺和诺德目标价，反映市场对其GLP-1商业化前景持续看好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648651733","title":"诺和诺德：符合条件的联邦医疗保险参保患者现在可按月自付50美元购得Wegovy。","url":"https://stock-news.laohu8.com/highlight/detail?id=2648651733","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648651733?lang=zh_cn&edition=full","pubTime":"2026-07-01 19:01","pubTimestamp":1782903695,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4599","BK4532","NVOH","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4007","NVO","NVOX","IE00BKVL7J92.USD","LU0154236417.USD","LU1093756325.SGD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647555250","title":"美国联邦医疗保险七月起首次覆盖减肥药物，诺和诺德股价应声上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2647555250","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647555250?lang=zh_cn&edition=full","pubTime":"2026-06-30 20:27","pubTimestamp":1782822420,"startTime":"0","endTime":"0","summary":"美国联邦医疗保险周一宣布，自7月1日起将首次覆盖选择性GLP-1类减肥药物，包括诺和诺德生产的司美格鲁肽注射剂。这意味着数千万Medicare参保人将有机会获得这类广受欢迎的减肥药物的报销资格。受此消息提振，诺和诺德股价在周一交易中上涨约0.6%。　　根据美国医疗保险与医疗补助服务中心发布的最终指南，此次覆盖适用于被诊断为肥胖症的患者，即体重指数达到30或以上的人群。此次政策调整是Medicare成立以来首次将减肥药物纳入常规报销体系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-30/doc-inifexfq1520001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4581","LU1791710582.SGD","LU1548497426.USD","LU2264538146.SGD","LU0912757837.SGD","LU0154236417.USD","LU0557290698.USD","LU1720051017.SGD","LU0528227936.USD","LU0225283273.USD","LU0053666078.USD","LU0158827948.USD","LU2111349929.HKD","LU1244550577.SGD","LU0234570918.USD","LU1064131342.USD","BK4534","LU0795875169.SGD","LU2487616109.SGD","LU2271345857.HKD","LU2347655156.SGD","LU0106261372.USD","LU0314104364.USD","LU0006306889.USD","LU1244550494.USD","LU2357305700.SGD","LU0267386448.USD","BK4588","BK4585","LU0320765646.SGD","BK4007","BK4516","LU2023251221.USD","LU2089283258.USD","IE00BKVL7J92.USD","BK4504","LU1162221912.USD","LU0390134368.USD","IE00BZ1G4Q59.USD","LU0098860793.USD","LU0106831901.USD","LU1093756168.USD","LU1668664300.SGD","LU1989772840.SGD","NVOH","LU2089284900.SGD","LU2028103732.USD","LU0210528500.USD","LU0795875086.SGD","LU1791710400.SGD","LU2133065610.SGD","LU1074936037.SGD","NVOX","LU0971096721.USD","LU1363072403.SGD","BK4532","LU1989772923.USD","LU1093756325.SGD","LU1732799900.SGD","LU1732800096.USD","LU0882574139.USD","NVO","BK4599","LU0158827781.USD","LU1244550221.USD","LU1988902786.USD","LU1720051108.HKD","BK4127","MS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647581242","title":"杰富瑞将诺和诺德目标股价从270丹麦克朗上调至285丹麦克朗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2647581242","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647581242?lang=zh_cn&edition=full","pubTime":"2026-06-30 12:03","pubTimestamp":1782792190,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4585","NVOH","BK4532","BK4599","LU0154236417.USD","LU1093756325.SGD","BK4007","NVOX","LU1093756168.USD","NVO","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646033697","title":"高盛将诺和诺德目标价从305丹麦克朗上调至310丹麦克朗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2646033697","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646033697?lang=zh_cn&edition=full","pubTime":"2026-06-26 13:03","pubTimestamp":1782450188,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NVOH","NVOX","BK4599","LU0154236417.USD","LU1093756325.SGD","BK4532","BK4588","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4007","NVO","BK4585","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646756628","title":"诺和诺德(NVO.US)美国负责人表示Wegovy口服剂型销量中直接面向消费者的销售占比达90%注射剂型该比例为30%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2646756628","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646756628?lang=zh_cn&edition=full","pubTime":"2026-06-25 17:03","pubTimestamp":1782378219,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NVOX","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","NVOH","BK4599","NVO","BK4007","LU0154236417.USD","BK4588","BK4532","LU1093756168.USD","BK4585","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646922817","title":"诺和诺德美国区总裁：公司正寻求小型配套并购，扩充产品管线。","url":"https://stock-news.laohu8.com/highlight/detail?id=2646922817","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646922817?lang=zh_cn&edition=full","pubTime":"2026-06-25 01:21","pubTimestamp":1782321671,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NVOX","IE00BKVL7J92.USD","BK4532","LU0154236417.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","LU1093756168.USD","NVO","BK4599","BK4588","BK4585","NVOH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646985817","title":"诺和诺德美国区总裁：尚不确定联邦医保是否会立刻加大该处方药报销支持力度。","url":"https://stock-news.laohu8.com/highlight/detail?id=2646985817","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646985817?lang=zh_cn&edition=full","pubTime":"2026-06-25 01:19","pubTimestamp":1782321543,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0154236417.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","NVOH","BK4007","LU1093756168.USD","BK4585","BK4599","BK4532","LU1093756325.SGD","NVOX","NVO","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646081762","title":"诺和诺德美国区总裁：联邦医保患者中，选择口服 GLP‑1 片剂的人数是注射剂的两倍。","url":"https://stock-news.laohu8.com/highlight/detail?id=2646081762","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646081762?lang=zh_cn&edition=full","pubTime":"2026-06-25 01:16","pubTimestamp":1782321382,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1093756325.SGD","NVOX","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4585","BK4599","BK4588","NVO","NVOH","LU0154236417.USD","LU1093756168.USD","BK4007","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109200815","title":"异动解读｜诺和诺德盘中上涨3.02%，司美格鲁肽中国数据保护期延长叠加CEO访华利好持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1109200815","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109200815?lang=zh_cn&edition=full","pubTime":"2026-06-24 03:28","pubTimestamp":1782242925,"startTime":"0","endTime":"0","summary":"6月24日，诺和诺德盘中上涨3.02%，报47.265美元/股，成交额6.59亿美元。消息面上，诺和诺德近期利好密集释放：公司CEO杜麦克明确王牌产品司美格鲁肽在中国的监管数据保护期将持续至明年4月，较核心化合物专利到期日晚一年多，据估算延长的13个月保护期可带来约10亿美元量级的额外稳定现金流。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645075769","title":"美股异动 | 诺和诺德(NVO.US)涨6% 司美格鲁肽中国市场保护期获延长","url":"https://stock-news.laohu8.com/highlight/detail?id=2645075769","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645075769?lang=zh_cn&edition=full","pubTime":"2026-06-22 23:19","pubTimestamp":1782141582,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，诺和诺德(NVO.US)涨6%，报45.79美元。消息面上，诺和诺德CEO近日明确，公司王牌产品司美格鲁肽在中国的监管数据保护期将持续至2027年4月，这比其核心化合物专利到期日(2026年3月)要晚一年多。据估算，这延长的13个月保护期能为公司带来约10亿美元量级的额外稳定现金流。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","NVOX","IE00BZ1G4Q59.USD","BK4532","IE00BKVL7J92.USD","NVO","LU0154236417.USD","LU1093756168.USD","LU1093756325.SGD","NVOH","BK4599","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152084680","title":"异动解读｜诺和诺德盘中上涨3.3%，CEO访华宣布口服减重药将递交中国上市申请并明确数据保护期至明年4月","url":"https://stock-news.laohu8.com/highlight/detail?id=1152084680","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152084680?lang=zh_cn&edition=full","pubTime":"2026-06-22 21:53","pubTimestamp":1782136428,"startTime":"0","endTime":"0","summary":"6月22日，诺和诺德盘中上涨3.3%，报44.995美元/股，成交额1.09亿美元。消息面上，诺和诺德全球CEO杜麦克首次访华期间密集释放利好：宣布计划数月内向中国监管机构递交口服版Wegovy上市申请，同时追加2亿元人民币投资用于天津注射笔组装产能扩充，并透露将增加在中国的BD交易。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164444065","title":"异动解读｜诺和诺德盘前涨超3%，CEO访华宣布口服减重药将递交中国上市申请并追加在华投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1164444065","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164444065?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:02","pubTimestamp":1782115361,"startTime":"0","endTime":"0","summary":"6月22日，诺和诺德盘前上涨3.26%，报44.44美元/股，成交额95.8万美元。消息面上，诺和诺德全球CEO杜麦克首次访华期间密集释放利好：宣布计划数月内向中国监管机构递交口服版Wegovy上市申请，同时追加2亿元人民币投资用于天津注射笔组装产能扩充，并透露未来将增加在中国的BD交易，正与多家中国公司保持对话。国际市场方面，口服Wegovy近期获英国药品监管机构批准，临床数据显示64周平均减重13.6%，中国申请叠加海外扩张强化了公司在GLP-1赛道的全球商业化前景。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺和诺德CEO访华宣布口服减重药将递交中国上市申请并追加在华投资","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110134524","title":"异动解读｜诺和诺德夜盘上涨3.15%，CEO访华宣布口服减重药将递交中国上市申请并追加在华投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1110134524","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110134524?lang=zh_cn&edition=full","pubTime":"2026-06-22 09:08","pubTimestamp":1782090528,"startTime":"0","endTime":"0","summary":"6月22日，诺和诺德夜盘上涨3.15%，报44.55美元/股，成交额164.82万美元。消息面上，诺和诺德全球CEO杜麦克近期首次访华期间密集释放利好：宣布计划数月内向中国监管机构递交口服版Wegovy上市申请，同时透露将增加在中国的BD交易，正与多家中国公司保持对话。国际市场方面，口服Wegovy近期获英国药品监管机构批准，临床数据显示64周平均减重13.6%，中国申请叠加海外扩张强化了公司在GLP-1赛道的全球商业化前景。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644054938","title":"链接世界，共创未来！丹麦诺和诺德公司董事会主席索文森寄语第四届链博会","url":"https://stock-news.laohu8.com/highlight/detail?id=2644054938","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644054938?lang=zh_cn&edition=full","pubTime":"2026-06-19 19:48","pubTimestamp":1781869680,"startTime":"0","endTime":"0","summary":"专题：第四届中国国际供应链促进博览会\n\n　　链接世界，共创未来！丹麦诺和诺德公司董事会主席索文森寄语第四届链博会。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张恒星","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-06-19/doc-inicxyys2720832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4599","BK4532","NVOH","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4007","NVO","NVOX","IE00BKVL7J92.USD","LU0154236417.USD","LU1093756325.SGD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167916166","title":"异动解读｜诺和诺德盘中上涨3.24%，CEO宣布将在中国递交口服Wegovy上市申请叠加英国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1167916166","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167916166?lang=zh_cn&edition=full","pubTime":"2026-06-17 21:37","pubTimestamp":1781703475,"startTime":"0","endTime":"0","summary":"6月17日，诺和诺德盘中上涨3.24%，报44.96美元/股，成交额6706.42万美元。诺和诺德全球CEO杜麦克表示，计划数月内向中国监管机构递交口服版Wegovy临床数据以寻求上市批准，同时透露未来在中国的BD交易将增加，正与多家中国公司保持对话。国际市场方面，口服Wegovy近期获英国药品监管机构批准，成为欧洲首个获批市场，临床数据显示64周平均减重13.6%，预计数周内通过私立处方上市。中国市场申请叠加海外持续扩张，强化了公司在GLP-1赛道的全球商业化前景。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":0.019},{"period":"1month","weight":0.1466},{"period":"3month","weight":0.3346},{"period":"6month","weight":-0.1292},{"period":"1year","weight":-0.2878},{"period":"ytd","weight":-0.0318}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":0.0186},{"period":"3month","weight":0.1396},{"period":"6month","weight":0.0895},{"period":"1year","weight":0.2014},{"period":"ytd","weight":0.1017}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球性的医疗保健公司，也是肥胖和糖尿病护理、制造和营销包括GLP-1受体激动剂和现代胰岛素在内的医药产品的世界领先企业。总部位于丹麦，业务遍及约80个国家，产品销往约170个国家。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.120105},{"month":2,"riseRate":0.6,"avgChangeRate":0.019219},{"month":3,"riseRate":0.444444,"avgChangeRate":0.006415},{"month":4,"riseRate":0.622222,"avgChangeRate":0.018023},{"month":5,"riseRate":0.565217,"avgChangeRate":0.019713},{"month":6,"riseRate":0.695652,"avgChangeRate":0.026728},{"month":7,"riseRate":0.5,"avgChangeRate":-0.001056},{"month":8,"riseRate":0.533333,"avgChangeRate":0.006145},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.002979},{"month":10,"riseRate":0.488889,"avgChangeRate":-0.004606},{"month":11,"riseRate":0.6,"avgChangeRate":0.026574},{"month":12,"riseRate":0.733333,"avgChangeRate":0.048757}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}